IPITA-IXA-CTRMS 2023

05:20-06:20

05:20
Indigo D

Indigo D

Industry Session: VitaCyte Symposium on Cell Isolation

Organized and Sponsored by:

Full Details

Balamurugan N. Appakalai, United States
Presenters:

Doug O'Gorman, Canada

Stephen Strom, Sweden

Stuart K. Williams, II, United States

05:30-06:25

05:30
Indigo A

Indigo A

Islet Transplantation: Addressing innate inflammation

Full Details

Haval Shirwan, United States
Co-engineering pancreatic islets with novel forms of thrombomodulin and CD47 as an effective means of mitigating instant blood-mediated inflammatory reaction

Tasneem R Abdel-Karim, United States
No differences in long-term diabetes outcomes with etanercept or alpha-1 antitrypsin treatment in total pancreatectomy and islet autotransplantation: A randomized controlled pilot study

ChaeRim Yoo, Korea
Neutralization of HMGB1 released from pancreatic islet via surface camouflage having glycol chitosan-glycyrrhizin conjugate

Mazhar A Kanak, United States
Islet stressomes released during isolation and in response to inflammation may affect outcomes in islet auto-transplantation

Cyril P Landstra, Netherlands
TNF-alpha blockade during islet transplantation in immunosuppressed recipients: a study on in vitro, clinical, and CITR registry-derived data

05:30-06:25

05:30
Indigo 204

Indigo 204

Cell therapies and others

Full Details

Swati Mishra, United States
Total pancreatectomy with islet auto-transplantation (TPIAT): Improving quality of life for patients with chronic pancreatitis at OHSU

Krishna Kumar Samaga, United States
Changes in portal pressure, blood glucose, and blood pressure levels during islet infusion in pediatric patients: Close monitoring for every five minutes during islet auto-transplantation

Rebecca M Spiers, United Kingdom
Reducing Neutral Protease Dose During Islet Isolation Does Not Impair Islet Recovery From Pancreases Retrieved for Autologous Use

Hany Abdelgawad, Germany
Generation and Characterization of Porcine derived Pseudo-Islets for Islet-cell Replacement

Toby Coates, Australia
Investigating GAD65-CAR Tregs as a Therapy for Type 1 Diabetes

05:30-06:25

05:30
Indigo H

Indigo H

Islet Xeno: Advancements in Engineered Porcine Islets for Xenotransplantation: Paving the Way for Transplant Success

Full Details

Lucky A Kalekar, United States
Pancreatic islets from genetically altered porcine donors are metabolically competent and cure diabetes in mice post xenotransplantation

Kyungmin Kwak, Korea
Islet xenotransplantation with quadruple knock-out porcine islet enhanced graft survival in diabetic mice

Sarah Grimus, Germany
Calcium sensor reporter pig model for assessment of beta-cell function

Wayne J Hawthorne, Australia
Optimising transgenic porcine neonatal islet cell cluster culture for use in pig-to-baboon xenotransplantation

06:30-07:30

06:30
Indigo A

Indigo A

Challenges in pancreas and islet transplantation (IPITA)

Supported by:

Full Details

Peter G. Stock, United States
Long term monitoring in pancreas and/or islet

Pablo Uva, Argentina
Diabetes that doesn't fall into transplantation

Marcelo Perosa, Brazil
What can we learn from large pancreas transplant programs

06:30-07:30

06:30
Indigo 204

Indigo 204

Complement, antibodies and coagulation (IXA)

Full Details

Richard N. Pierson III, United States
Xeno-antibodies

Peter Cowan, Australia
Complement and complement inhibitors

Robert Rieben, Switzerland
Coagulation and Cogulation inhibitors

06:30-07:30

06:30
Indigo D

Indigo D

Complex tissue and organ bioengineering (CTRMS)

Full Details

Jason Wertheim, United States
Novel applications to organoid technology

Csaba Adori, Sweden
Disorganization and degeneration of liver sympathetic innervations in nonalcoholic fatty liver disease revealed by 3D imaging

Xi (Charlie) Ren, United States
Engineering the vascular bed for complex organ manufacturing

06:30-07:30

06:30
Indigo H

Indigo H

Engineering the site (Joint)

Full Details

Alice Tomei, United States
Transplantation of conformal coated islets in a pre-vascularized Cell Pouch™ device for beta cell replacement in diabetic rats

Andrew Pepper, Canada
Bioengineered Scaffolds To Augment Islet Engraftment

Antonio Citro, Italy
Islet Engraftment: Unveiling the Puzzle Pieces in the Quest for Understanding

07:30-08:00

07:30
Foyer Area

Foyer Area

Coffee Break

Full Details

08:00-09:30

08:00
Indigo BC

Indigo BC

Keynote and Paul Lacy Lectures

Full Details

Doris A Taylor, United States
Bioengineering Humans Organs in 2023: Getting to the Heart of It All

Bernhard J. Hering, United States
2023 Paul E. Lacy Memorial Lecture Award on Dr. Lacy's Legacy: The Missing Link

09:35-10:35

09:35
Indigo A

Indigo A

Pre-clinical and clinical application of xenotransplantation and current barriers 3

Full Details

Jan-Michael Abicht, Germany
Non-thrombogenic costimulation blockade in preclinical cardiac xenotransplantation using a combination of anti-CD40L PAS Fab and chimeric anti-CD40 antibody

Seung Hyeun Lee, Korea
Comparative clinical analysis in pig-to-rhesus corneal xenotransplantation depending on various immunosuppressants

Cullen Soares, United States
Invasive versus Echocardiographic Hemodynamics in the First Genetically Modified Porcine to Human Xenotransplant

Yifan Yu, People's Republic of China
Clinical subjects may suitable for renal xenotransplantation because of lower anti-pig antibodies

Joon Young Jang, Korea
Beneficial effects of transgenic expression of human CD200 on top of quadruple-knockout/double-knockin (CD46/thrombomodulin) pigs on kidney xenograft survival in nonhuman primates

09:35-10:35

09:35
Indigo 204

Indigo 204

Cell-based immune therapy for transplantation

Full Details

Mizuki Inage, Japan
Therapeutic potential of myeloid-derived suppressor cells in islet transplantation

Agustina Forgioni, Japan
Efficacy of ex-vivo generated donor antigen-specific immunomodulatory cells on pancreatic islet transplantation

Masaki MH Harada, Japan
CD80/CD86-CD28 costimulatory block enhance the regulatory T cell function with specificity and prolong islet allograft acceptance

Yuki Y Imaoka, United States
Identifying High TRAIL-Expressing Liver NK Cells from Deceased and Living Donors for Effective Immunotherapy

Roberto Gramignoli, Sweden
Human Amnion Epithelial Cells reduce disease progression in a mouse model for multiple sclerosis

Reza F. Saidi, United States
Pancreas After Kidney Transplantation Outcomes Over the Past 20 Years in the USA

09:35-10:35

09:35
Indigo D

Indigo D

Concurrent Session: AHP: An overview of differing practice, policy and procedure within the pancreas and islet cell transplant communities

Full Details

Colleen J Etherton, Australia
Australian experience on Pancreas and Islet cell transplantation

Robyn L Bilawey, Canada
Edmonton experience on Pancreas and Islet transplantation

Emily Scheidecker, United States
Auto Islet Transplantation

09:35-10:35

09:35
Indigo H

Indigo H

Donor genetic modification for xenotransplantation 2

Full Details

Dengke Pan, People's Republic of China
Preparation of GTKO/SdaKO/CMAHKO/hCD46/hCD55/hTHBD pig with high expression level of human CD55 through a transgene strategy

Kasinath V Kuravi, United States
Molecular characterization of donor pig of the first human xeno-heart transplant

Maria Kokkinaki, United States
A case study of PCR-based PCMV detection in the donor pig of first xenoheart transplant into a human patient.

Nizar I Mourad, Belgium
Xenotransplantation of functionally improved neonatal pig islets

Shuji - Miyagawa, Japan
The hybrid molecule CL-SP-D has the potential to regulate xenogeneic rejection by human neutrophils

Wenning Qin, United States
Design and creation of a clinically compatible porcine donor for xenotransplantation

10:35-12:00

10:35
Hilton lobby area

Hilton lobby area

Lunch Break

Full Details

10:50-11:50

10:50
Indigo BC

Indigo BC

Revivicor / United Therapeutics Symposium

Organized and Sponsored by:

Full Details

Muhammad Mohiuddin, United States
Progress in cardiac xenotransplantation: Research from mouse to human

Kazuhiko Yamada, United States
Experience with 10GE pig kidneys and GalTKO thymokidneys towards clinical trials

12:00-13:30

12:00
Indigo A

Indigo A

IPITA Special Lecture / Business Meeting & Awards

Full Details

James F. Markmann, United States
Introduction of Richard C. Lillehei Award Recipient

Stephen T. Bartlett, United States
Richard C. Lillehei: His remarkable legacy of scientific discovery

Raja Kandaswamy, United States
IPITA Business Meeting

Thomas W.H. Kay, Australia
Presentation of the Derek Grey, Sutherland and Scientific Congress Awards

12:00-13:30

12:00
Indigo 204

Indigo 204

Concurrent Session: Modifications and Microbes (IXA)

Full Details

Peter Cowan, Australia
Genetic Modification in donors for islet xenotransplantation

Eckhard Wolf, Germany
Genetic modification in donors for solid organ

David L. Ayares, United States
Genetic modification in clinical trials

Jay A. Fishman, United States
What do we need to be concerned about?

Joachim Denner, Germany
What testing should be done for PCMV/PRV?

Ralf R Tönjes, Germany
Data sharing for regulatory application

12:00-13:40

12:00
Indigo D

Indigo D

Concurrent Session: Translation of regenerative medicine technologies to the clinic (CTRMS)

Full Details

Markus Grompe, United States
Therapeutic liver repopulation by transient acetaminophen selection of gene-modified hepatocytes

Michael Oertel, United States
The role of Activin A-signaling in cell transplantation, liver regeneration and fibrosis

Paul S. Larson, United States
Cell Therapy for Parkinson’s - Clinical trials

Shin SE Enosawa Dr, Japan
Stem cells clinical trial in Japan and brief historical perspective and current status

Rick Silva, United States
Cell therapy at the Industry-Academic interface: Clinical, regulatory, and commercial lessons learned from advances in the CAR-T field

12:00-13:30

12:00
Indigo H

Indigo H

Oral Abstract Session: Organ, tissue and organoids manufacturing

Full Details

Fanny Lebreton, Switzerland
Hydrogel-based, prevascularized, retrievable endocrine construct to treat Type 1 Diabetes

Kevin Bellofatto, Switzerland
Vascularized endocrine pancreas for type 1 diabetes

Michał Wszoła, Poland
3D bioprinting of a bionic pancreas with a vascular system - results of transplantation in large animals.

Andrzej Berman, Poland
Insulin-independence of diabetic pigs after autotransplantation of 3D-bioprinted bionic pancreatic tissue petals.

Antonio Citro, Italy
Bioengineering of an iPSC-derived vascularized endocrine pancreas (iVEP) for T1D

Brenden N. Moeun, Canada
Vascularizing a human-scale bioartificial pancreas using sacrificial embedded 3D printing into self-healing alginate

Hidetaka Hara, People's Republic of China
In vitro and in vivo immune assessments of TKO pig skin grafts in New World (squirrel) monkeys

Marta Klak, Poland
Artificial pancreatic islets produced by 3D bioprinting ink-jet technology with extracellular matrix as an environment for stem-cell derived beta cells.

Carolin Heller, Germany
Microarrangement of Islets to prevent Hypoxia within a Macroencapsulation Device

13:30-14:00

13:30
Foyer Area

Foyer Area

Coffee Break

Full Details

14:00-15:30

14:00
Indigo A

Indigo A

Islet Transplantation: Isolating and assessing islets better

Full Details

Krishna Kumar Samaga, United States
Dosing rC1 and rC2 collagenases based on percent parenchymal mass improves digestion efficacy of fibrotic chronic pancreatitis pancreases intended for pediatric islet auto-transplantation

Chris Orr PhD, United States
Optimization of Islet Isolation Methodology with Data Modeling and Decision Support

Meirigeng Qi, United States
Large-scale long-term 3D-hydrogel culture yields high-quality islets suitable for transplantation

Koya Shinohara, Japan
New pancreatic islet purification method in pancreatic islet isolation applying photoimmunotherapy.

Julie Kerr-Conte, France
SEPAX -SEFIA a repurposed closed system for human islet purification and processing in cGMP environment

David Habart, Czech Republic
Novel models for predicting the volume and the cell content of individual islets from 2D-microscopic projections for islet graft quality control.

Doug O'Gorman, Canada
Analysis of collagenase dose on allogeneic islet isolation outcomes and glucose-stimulated insulin release

Rebecca Lawless, United States
Quantitative analysis of microbial contamination in islet isolation for total pancreatectomy and islet auto transplantation (TPIAT): development of bioburden reduction strategies

14:00-14:40

14:00
Indigo 204

Indigo 204

Concurrent Session: Road to Xenotransplantation Clinical Trials: Decedent Model: A supplement or the substitute (IXA)

Full Details

Muhammad Mohiuddin, United States
Introduction to the session

Robert A Montgomery, United States
Advantages of switching to a Decedent Model

Alfred J. Tector, United States
Advantages of IND enabling NHP studies

Patricia Beaston, United States
FDA Perspective

14:00-15:30

14:00
Indigo D

Indigo D

Inflammatory responses, innate and adaptive immunity

Full Details

Shuji - Miyagawa, Japan
The suppression of xenogeneic NK cell degranulation by human CD31

Ping Li, United States
Synergistic inhibition of human NK cell activation by co-expression of HLA-E and HLA-G on porcine endothelial cells

Xiaoqian Ma, People's Republic of China
4-Octyl itaconate reverses metabolic reprogramming of T cells in aGVHD by partial inhibition of GAPDH

Konrad Fischer, Germany
Evaluation of immune reactions in multi-knockout kidneys after perfusion with human blood

Hidetaka Hara, People's Republic of China
The molecular mechanism, function, and therapeutic targeting of the CD40-CD154 pathway in xenotransplantation: a review

Nick Esch, United States
Amplification-free activation of primate complement by porcine triple-knockout cells is driven by the classical pathway

Viktoriia Galdina, Switzerland
Generation and functional assessment of human anti-pig cytotoxic T cells

Jörg D. Seebach, Switzerland
HLA-E protects genetically engineered porcine endothelial cells from lysis by natural killer cells in 2D and 3D microfluidic systems

14:00-15:30

14:00
Indigo H

Indigo H

Pancreas Transplantation: Exploring multifaceted approaches for improvement

Full Details

Devprakash Choudhary, India
Simultaneous Pancreas and Kidney Transplantation Utilizing Donors Younger than Five Years

Pedro Ventura-Aguiar, Spain
Simultaneous kidney-pancreas transplantation improves endothelial dysfunction induced by extracellular vesicles

Christopher J. Webb, United States
Improved outcomes following simultaneous pancreas-kidney transplantation in the second decade of the new millennium: a single center longitudinal analysis by era

Richard Knight, United States
Early differences in glucose homeostasis between diabetes type 1 versus type 2 recipients of kidney/pancreas transplants

Konstantinos Zorbas, United States
Postoperative Complications after Pancreas Transplantation – A single center analysis

Angelika C. Gruessner, United States
Global developments in Pancreas Transplantation with special Emphasis on the impact of COVID-19 – A Registry Report

Angelika C. Gruessner, United States
Pancreas transplantation – An Option after Total Pancreatectomy without Islet Auto Transplantation (IAT)

Diego Cantarovich, France
Anti-TNFα as an adjunctive therapy in pancreas transplantation

Marcelo Perosa, Brazil
Does lymphocyte count after rabbit antithymocyte globulin induction therapy matter in pancreas transplantation?

14:40-15:30

14:40
Indigo 204

Indigo 204

Concurrent Session: Road to Xenotransplantation Clinical Trials: Expanded Access Program (IXA)

Full Details

Bartley P. Griffith, United States
Advantages of eIND learned through experience

Patricia Beaston, United States
FDA perspective for future eINDs Vs. INDs

Ralf R Tönjes, Germany
Status of Clinical Trials outside the United States

17:00-20:00

17:00
Hilton lobby area

Hilton lobby area

Congress Networking Event ($)

Full Details

05:30 - 06:25 | Oral Abstract Sessions

06:30 - 07:30 | Concurrent Sessions

07:30 - 08:00 | Coffee Break and Exhibit Area

08:00 - 09:30 | Keynote Lectures

09:35 - 10:35 | Oral Abstracts and Allied Health Sessions

10:35 - 12:00 | Lunch Break and Industry Symposium

12:00 - 13:30 | Concurrents and Abstract Sessions

13:30 - 14:00 | Coffee Break

14:00 - 15:30 | Oral Abstracts Sessions / IXA Workshop

17:00 - 20:00 | Networking Events

Organized by

Supported by

Hosted by